166 related articles for article (PubMed ID: 20941544)
1. Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold.
Brugaletta S; Garcia-Garcia HM; Garg S; Gomez-Lara J; Diletti R; Onuma Y; van Geuns RJ; McClean D; Dudek D; Thuesen L; Chevalier B; Windecker S; Whitbourn R; Dorange C; Miquel-Hebert K; Sudhir K; Ormiston JA; Serruys PW
Int J Cardiovasc Imaging; 2011 Jul; 27(6):859-66. PubMed ID: 20941544
[TBL] [Abstract][Full Text] [Related]
2. Analysis of 1 year virtual histology changes in coronary plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold.
Brugaletta S; Gomez-Lara J; Garcia-Garcia HM; Heo JH; Farooq V; van Geuns RJ; Chevalier B; Windecker S; McClean D; Thuesen L; Whitbourn R; Meredith I; Dorange C; Veldhof S; Rapoza R; Ormiston JA; Serruys PW
Int J Cardiovasc Imaging; 2012 Aug; 28(6):1307-14. PubMed ID: 22108907
[TBL] [Abstract][Full Text] [Related]
3. Reproducibility of Shin's method for necrotic core and calcium content in atherosclerotic coronary lesions treated with bioresorbable everolimus-eluting vascular scaffolds using volumetric intravascular ultrasound radiofrequency-based analysis.
Shin ES; Garcia-Garcia HM; Sarno G; Thuesen L; Dudek D; Ormiston JA; Serruys PW
Int J Cardiovasc Imaging; 2012 Jan; 28(1):43-9. PubMed ID: 21229393
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the serial changes of vessel wall contents in atherosclerotic coronary lesion with bioresorbable everolimus-eluting vascular scaffolds using Shin's method: an IVUS study.
Shin ES; Garcia-Garcia HM; Garg S; Ligthart J; Thuesen L; Dudek D; Ormiston JA; Serruys PW
Int J Cardiovasc Imaging; 2011 Oct; 27(7):931-7. PubMed ID: 21080074
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial.
García-García HM; Gonzalo N; Pawar R; Kukreja N; Dudek D; Thuesen L; Ormiston JA; Regar E; Serruys PW
EuroIntervention; 2009 Jan; 4(4):443-8. PubMed ID: 19284065
[TBL] [Abstract][Full Text] [Related]
6. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial.
Gogas BD; Serruys PW; Diletti R; Farooq V; Brugaletta S; Radu MD; Heo JH; Onuma Y; van Geuns RJ; Regar E; De Bruyne B; Chevalier B; Thuesen L; Smits PC; Dudek D; Koolen J; Windecker S; Whitbourn R; Miquel-Hebert K; Dorange C; Rapoza R; Garcia-Garcia HM; McClean D; Ormiston JA
JACC Cardiovasc Interv; 2012 Jun; 5(6):656-65. PubMed ID: 22721662
[TBL] [Abstract][Full Text] [Related]
7. Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study.
Brugaletta S; Garcia-Garcia HM; Diletti R; Gomez-Lara J; Garg S; Onuma Y; Shin ES; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Chevalier B; McClean D; Windecker S; Whitbourn R; Dorange C; Veldhof S; Rapoza R; Sudhir K; Bruining N; Ormiston JA; Serruys PW
EuroIntervention; 2011 Apr; 6(9):1110-6. PubMed ID: 21518685
[TBL] [Abstract][Full Text] [Related]
8. Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial.
Brugaletta S; Gomez-Lara J; Serruys PW; Farooq V; van Geuns RJ; Thuesen L; Dudek D; Koolen J; Chevalier B; McClean D; Windecker S; Smits PC; de Bruyne B; Whitbourn R; Meredith I; van Domburg RT; Sihan K; de Winter S; Veldhof S; Miquel-Hebert K; Rapoza R; Garcia-Garcia HM; Ormiston JA; Bruining N
JACC Cardiovasc Interv; 2011 Dec; 4(12):1281-9. PubMed ID: 22192369
[TBL] [Abstract][Full Text] [Related]
9. Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial.
Sarno G; Bruining N; Onuma Y; Garg S; Brugaletta S; De Winter S; Regar E; Thuesen L; Dudek D; Veldhof S; Dorange C; Garcia-Garcia HM; Ormiston JA; Serruys PW
Int J Cardiovasc Imaging; 2012 Jan; 28(1):51-8. PubMed ID: 21213050
[TBL] [Abstract][Full Text] [Related]
10. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
[TBL] [Abstract][Full Text] [Related]
11. Comparative assessment of "plaque/media" change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study.
Zeng Y; Cavalcante R; Tenekecioglu E; Suwannasom P; Sotomi Y; Collet C; Abdelghani M; Jonker H; Digne F; Horstkotte D; Zehender M; Indolfi C; Saia F; Fiorilli R; Chevalier B; Bolognese L; Goicolea J; Nie S; Onuma Y; Serruys PW;
Int J Cardiovasc Imaging; 2017 Apr; 33(4):441-449. PubMed ID: 28012050
[TBL] [Abstract][Full Text] [Related]
12. Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study.
Bruining N; de Winter S; Roelandt JR; Regar E; Heller I; van Domburg RT; Hamers R; Onuma Y; Dudek D; Webster MW; Thuesen L; Ormiston JA; Cheong WF; Miquel-Hebert K; Veldhof S; Serruys PW
JACC Cardiovasc Interv; 2010 Apr; 3(4):449-56. PubMed ID: 20398874
[TBL] [Abstract][Full Text] [Related]
13. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
[TBL] [Abstract][Full Text] [Related]
14. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
[TBL] [Abstract][Full Text] [Related]
15. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
[TBL] [Abstract][Full Text] [Related]
16. Intimal hyperplasia and vascular remodeling after everolimus-eluting and sirolimus-eluting stent implantation in diabetic patients: the randomized Diabetes and Drug-Eluting Stent (DiabeDES) IV Intravascular Ultrasound trial.
Antonsen L; Maeng M; Thayssen P; Christiansen EH; Hansen KN; Kaltoft A; Hansen HS; Thuesen L; Lassen JF; Jensen LO
Catheter Cardiovasc Interv; 2014 May; 83(6):864-72. PubMed ID: 23996918
[TBL] [Abstract][Full Text] [Related]
17. Acute Gain in Minimal Lumen Area Following Implantation of Everolimus-Eluting ABSORB Biodegradable Vascular Scaffolds or Xience Metallic Stents: Intravascular Ultrasound Assessment From the ABSORB II Trial.
Sotomi Y; Ishibashi Y; Suwannasom P; Nakatani S; Cho YK; Grundeken MJ; Zeng Y; Tateishi H; Smits PC; Barragan P; Kornowski R; Gershlick AH; Windecker S; van Geuns RJ; Bartorelli AL; de Winter RJ; Tijssen J; Serruys PW; Onuma Y
JACC Cardiovasc Interv; 2016 Jun; 9(12):1216-1227. PubMed ID: 27339838
[TBL] [Abstract][Full Text] [Related]
18. Scaffold and edge vascular response following implantation of everolimus-eluting bioresorbable vascular scaffold: a 3-year serial optical coherence tomography study.
Zhang YJ; Iqbal J; Nakatani S; Bourantas CV; Campos CM; Ishibashi Y; Cho YK; Veldhof S; Wang J; Onuma Y; Garcia-Garcia HM; Dudek D; van Geuns RJ; Serruys PW;
JACC Cardiovasc Interv; 2014 Dec; 7(12):1361-9. PubMed ID: 25457053
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.
Suwannasom P; Sotomi Y; Ishibashi Y; Cavalcante R; Albuquerque FN; Macaya C; Ormiston JA; Hill J; Lang IM; Egred M; Fajadet J; Lesiak M; Tijssen JG; Wykrzykowska JJ; de Winter RJ; Chevalier B; Serruys PW; Onuma Y
JACC Cardiovasc Interv; 2016 Jun; 9(12):1231-1242. PubMed ID: 27262861
[TBL] [Abstract][Full Text] [Related]
20. Randomized Comparison Between Everolimus-Eluting Bioresorbable Scaffold and Metallic Stent: Multimodality Imaging Through 3 Years.
Onuma Y; Honda Y; Asano T; Shiomi H; Kozuma K; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Hanaoka KI; Tanabe K; Okada K; Kitahara H; Ono M; Kusano H; Rapoza R; Simonton C; Popma JJ; Stone GW; Fitzgerald PJ; Serruys PW; Kimura T
JACC Cardiovasc Interv; 2020 Jan; 13(1):116-127. PubMed ID: 31918929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
